Haloperidol attenuates β-amyloid-induced calcium imbalance in human fibroblasts

Skin Pharmacology and Physiology

Volumn 17, Issue 4, 2004, Pages 195-199

  Palotas A ^a   Penke, B ^a   Palotas M ^a   Kenderessy, A Sz ^a   Kemeny L ^a   Kis, E ^a   Vincze, G ^b   Janka, Z ^a   Kalman J ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b Pandy Kalman County Hospital   (Hungary)

Author keywords

amyloid peptide; Alzheimer's disease; Calcium; Fibroblast; Fluorescence; Haloperidol; Schizophrenia

Indexed keywords

AMYLOID BETA PROTEIN; CALCIUM; DOPAMINE 2 RECEPTOR; FURA 2 ACETOXYMETHYL ESTER; HALOPERIDOL; SIGMA 1 OPIATE RECEPTOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CALCIUM BALANCE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; INCUBATION TIME; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPECTROFLUOROMETRY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTIPSYCHOTIC AGENTS; CALCIUM; CELLS, CULTURED; FIBROBLASTS; HALOPERIDOL; HUMANS; SPECTROMETRY, FLUORESCENCE;

EID: 3242805334     PISSN: 16605527     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078823     Document Type: Article

References (29)

1. 2+ homeostasis in Alzheimer's disease. Trends Neurosci 1993;16:409-414.
2. Soininen H, Syrjanen S, Heinonen O, Neittaanmaki H, Miettinen R, Paljarvi L, Syrjanen K, Beyreuther K, Riekkinen P: Amyloid betaprotein deposition in skin of patients with dementia. Lancet 1992;339:245.
3. Peterson C, Gibson GE, Blass JP: Altered calcium uptake in cultured skin fibroblasts from patients with Alzheimer's disease. N Engl J Med 1985;312:1063-1065.
4. Sims NR, Finegan JM, Blass JP: Altered glucose metabolism in fibroblasts from patients with Alzheimer's disease. N Engl J Med 1985; 313:683-684.
5. Li JC, Kaminskas E: Deficient repair of DNA lesions in Alzheimer's disease fibroblasts. Biochem Biophys Res Commun 1985;129:733-738.
6. Paoletti F, Tombaccini D: Proteolytic imbalance in Alzheimer fibroblasts as potential pathological trait of disease. FASEB J 1998;12: 925-927.
7. Arnold SE, Franz BR, Trojanowski JQ: Elderly patients with schizophrenia exhibit infrequent neurodegenerative lesions. Neurobiol Aging 1994;15:299-303.
8. Casanova MF, Carosella NW, Gold JM, Kleinman JE, Weinberger DR, Powers RE: A topographical study of senile plaques and neurofibrillary tangles in the hippocampi of patients with Alzheimer's disease and cognitively impaired patients with schizophrenia. Psychiatry Res 1993;49:41-62.
9. Crawford KW, Bowen WD: Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res 2002;62:313-322.
10. Mitchell IJ, Cooper AC, Griffiths MR, Cooper AJ: Acute administration of haloperidol induces apoptosis of neurones in the striatum and substantia nigra in the rat. Neuroscience 2002;109:89-99.
11. Prokopenko RA, Mogilevich SE, Luik AI, Naydyenova IY, Batrak GN, Hawryluk BR, Degtiar VY: Effects of haloperidol and chlorpromazine on smooth muscle contractility, platelet aggregation and neuronal calcium current. Gen Physiol Biophys 1995;14:349-357.
12. Borc JJ, Larson DB, Lyons JS, Beardsley RS: Expenditures for psychotropic medications in the United States. Am J Psychiatry 1991;148: 644-647.
13. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, 1994.
14. ilevel of fibroblasts from Alzheimer patients and control individuals. Neurochem Res 2001; 26:817-820.
15. Eckert A, Forstl H, Hartmann H, Czech C, Monning U, Beyreuther K, Muller WE: The amplifying effect of beta-amyloid on cellular calcium signalling is reduced in Alzheimer's disease. Neuroreport 1995;6:1199-1202.
16. Palotás A, Kálmán J, Palotás M, Juhász A, Janka Z, Penke B: β-Amyloid-induced increase in the resting intracellular calcium concentration gives support to tell Alzheimer lymphocytes from control ones. Brain Res Bull 2002;58: 203-205.
17. Sevush S, Jy W, Horstman LL, Mao WW, Kolodny L, Ahn YS: Platelet activation in Alzheimer disease. Arch Neurol 1998;55:530-536.
18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagents. J Biol Chem 1951;193:265-275.
19. Stewart JM, Young JD: Solid Phase Peptide Synthesis, ed 2. Pierce, Rockford,1984.
20. Volavka J, Cooper TB: Review of haloperidol blood level and clinical response: Looking through the window. J Clin Psychopharmacol 1987;7:25-30.
21. VanPutten T, Marder SR, Mintz J, Poland RE: Haloperidol plasma levels and clinical response: A therapeutic window relationship. Psychopharmacol Bull 1988;24:172-175.
22. 2+ channels in hippocampal neurones. Eur J Pharmacol 1994;267:249-252.
23. Santi CM, Cayabyab FS, Sutton KG, McRory JE, Mezeyova J, Hamming KS, Parker D, Stea A, Snutch TP: Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci 2002;22:396-403.
24. 2+-channel hypothesis for neuronal death in Alzheimer disease. Mol Cell Biochem 1994; 140:119-125.
25. Kagan BL, Hirakura Y, Azimov R, Azimova R, Lin MC: The channel hypothesis of Alzheimer's disease: Current status. Peptides 2002; 23:1311-1315.
26. Higaki J, Murphy GM Jr, Cordell B: Inhibition of β-amyloid formation by haloperidol: A possible mechanism for reduced frequency of Alzheimer's disease pathology in schizophrenia. J Neurochem 1997;68:333-336.
27. Kontkanen O, Toronen P, Lakso M, Wong G, Castren E: Antipsychotic drug treatment induces differential gene expression in the rat cortex. J Neurochem 2002;83:1043-1053.
28. Edell WS, Tunis SL: Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric inpatients. Am J Geriatr Psychiatry 2001;9:289-297.
29. Herrmann N, Black SE: Behavioral disturbances in dementia: Will the real treatment please stand up? Neurology 2000;55:1247-1248.